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Reply to: ‘‘The impact of organ dysfunction in cirrhosis:
Survival at a cost?’’
To the Editor:
The danger of comparing survival rates from chronic liver
disease cohorts with differing levels of organ failure severity
Conﬂict of interest
JOURNAL OF HEPATOLOGYWe thank Thomson and colleagues for their comments on our
recent article [1], one of the largest prospective studies ever pub-
lished on intensive care provision and cost utilisation for patients
with chronic liver disease. In their letter, they correctly note the
inherent difﬁculty in comparing different datasets. The subse-
quent comparisons and conclusions they make regarding better
outcomes for these patients at non-transplant centres are how-
ever difﬁcult to justify, as we will demonstrate.
We analysed 563 patients between 2000 and 2007 with a
median APACHE II score of 22[1]. Thomson et al. refer to a
recently published data set [2] of 118 patients from two different
London institutions without in-house liver transplantation facili-
ties between 2007 and 2009 with a median APACHE II score of 19.
While they suggest the mortality rates are different between the
two datasets, this could potentially be entirely explained by dif-
fering levels of organ failure severity between the two cohorts.
The APACHE II risk of death (ROD) [3,4] is designed to partly over-
come the clear potential for bias in directly comparing mortality
between different critical care units with different case mixes and
failure to compare to the predicted mortality rate leads to inap-
propriate conclusions on individual unit performance. While a
rudimentary tool and not validated in all groups admitted to
intensive care, it is instructive to make the following cohort com-
parison assuming all patients met the APACHE II chronic liver dis-
ease criteria. In the Thomson et al. cohort, the predicted ROD
would be 49% while their actual rate is 47%. A Chi squared test
(v2) between observed and predicted survival gives a p value of
0.748. In our cohort, the predicted ROD is 55% (actual 59%) and
a v2 test again gives a non-signiﬁcant p value of 0.189. Therefore
both cohorts have mortality rates within the range predicted for
the organ severity of the admitted patients.
Secondly, comparing datasets of different chronologies is
highly problematic given the signiﬁcant improvement in critical
care provision during the study periods of both publications. To
answer this, we looked at a cohort chronologically matched to
that of Thomson et al. from our institution, comprising 218
patients with cirrhosis between 31 October 2007 and 31 October
2009. The median APACHE II score was 21 with an APACHE II pre-
dicted mortality of 51% and actual mortality of 51% (obs-exp v2 p
value = 1). Comparing, without APACHE II adjustment, to the
cohort of Thomson et al. again demonstrated no survival differ-
ence (p = 0.525). However, whether this is an effect of our shared
local patient base or critical care organisation is not known. All
we can say is that there is no deﬁnitive statistical evidence toJournal of Hepatology 20suggest a mortality difference between the transplant and
non-transplant centres compared outside of what would be
expected from the difference in underlying severity of illness.
National patient level data would be required to deﬁnitively
address this question.
Finally, Thomson et al. did not give information on cost utilisa-
tion at their study institutions and this was a key message of our
article and one likely to be of signiﬁcant importance given expan-
sion in both critical care provision and incidence of chronic liver
disease. Our primary message on the cost-beneﬁt analysis in
treating patients with chronic liver disease in intensive care is
in the transplant centre setting and it would be interesting to
know what the cost utilisation is at non-specialist centres. We
therefore uphold the statement that given the increased number
of admissions to critical care facilities expected from patients
with chronic liver disease, our analysis suggests that many of
these patients will beneﬁt from admission to intensive care.The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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